Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber.

Next Previous
Trial Profile

A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cat SPIRE (Primary)
  • Indications Hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Circassia; Niox

Most Recent Events

  • 25 Feb 2013 Two-year results have been presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) according to a Circassia media release. Results were also reported in the media release.
  • 13 Sep 2012 Results published in the Journal of Allergy and Clinical Immunology.
  • 25 May 2012 Two-year extension study record identified and integrated (ClinicalTrials.gov record NCT01604018).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top